Share capital increase registered | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16330
post-template-default,single,single-post,postid-16330,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Share capital increase registered

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the “Company”) on 15 June 2018 regarding a private placement towards Vatne Equity AS and Norron AB, by issuance of 1,399,628 new shares in the Company at a subscription price of NOK 50 per new share.

The share capital increase pertaining to the private placement is now registered with the Norwegian Register of Business Enterprises. The Company’s new registered share capital is NOK 1,539,592.10 divided on 15,395,921 shares, each with a nominal value of NOK 0.10.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Njaal Kind
Group CFO, Gentian Diagnostics AS
njaal.kind@gentian.no
+47 9190 6525

 

MeldingsID: 455507
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: KAPITAL- OG STEMMERETTSENDRINGER
Informasjonspliktige opplysninger: Ja